UK markets closed

Lexicon Pharmaceuticals, Inc. (LXRX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.6350-0.0750 (-4.39%)
As of 02:49PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close1.7100
Open1.7100
Bid1.6300 x 200
Ask1.6400 x 200
Day's range1.6300 - 1.7800
52-week range0.9200 - 3.7900
Volume1,981,166
Avg. volume4,889,020
Market cap402.597M
Beta (5Y monthly)1.27
PE ratio (TTM)N/A
EPS (TTM)-0.8000
Earnings date30 Apr 2024 - 06 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est5.33
  • GlobeNewswire

    Lexicon Pharmaceuticals to Host 2024 Investor Day

    Includes Business and Scientific Updates from Lexicon Executives and Leading Medical Experts in Hypertrophic Cardiomyopathy, Type 1 Diabetes and Diabetic Peripheral Neuropathic PainTHE WOODLANDS, Texas, April 18, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that senior company executives will be joined by leading physicians at the Lexicon 2024 Investor Day on April 22, 2024. The event will be held in New York City from 9:00 a.m. to 12:00 p.m. ET. Business

  • Zacks

    All You Need to Know About Lexicon (LXRX) Rating Upgrade to Buy

    Lexicon (LXRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

  • GlobeNewswire

    Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference

    THE WOODLANDS, Texas, April 03, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced Jeff Wade, Lexicon’s president and chief financial officer, Tom Garner, Lexicon’s senior vice president and chief commercial officer, and Craig Granowitz, M.D., Ph.D., Lexicon’s senior vice president and chief medical officer, will participate in a moderated discussion at the 23rd Annual Needham Virtual Healthcare conference Wednesday April 10th, 1:30-2:10pm. A simultaneous webca